Development and optimization of tibezonium iodide and lignocaine hydrochloride containing novel mucoadhesive buccal tablets: a pharmacokinetic investigation among healthy humans

Exorbitant Drug Loading of Metformin and Sitagliptin in Mucoadhesive Buccal Tablet: In Vitro and In Vivo Characterization in Healthy Volunteers

“…For f2, the values of SIT and MET were found to be 62.35 and 67.47, correspondingly, while for f2, the values were 7.17 and 5.88, respectively. These factors were found to be in accordance with the acceptable limit of the similarity (50-100) and dissimilarity (0-15) ranges [11], which conforms that the release profile of the formulation did not differ significantly for both SIT and MET (Table 6). Consequently, the solid form was considered stable during the storage time period under the specified conditions (stability zone IVa).…”

“…It was then placed inside the heating chamber of the machine that scanned heat into the system over a range of 40-300 • C at an incremental speed of 20 • C/min. The gas was purged at a rate of 50 mL/min [11].…”

“…Each tablet was then kept in a Petri dish over a glass slide containing 10 mL of distilled water adjusted to pH 6.8 in such a way that half of the tablet remained immersed in the medium. After intervals of 0.5, 1, 2, 4 and 6 h, the tablets were withdrawn from the Petri dishes and the swollen tablets were reweighed (W2) in order to measure the weight gained by the respective tablet [11]. The degree of swelling was calculated as (Equation ( 2)).…”

“…Therefore, we addressed these concerns in our research via the formulation of buccal mucoadhesive tablets to ensure sustained systemic drug release with a low frequency of dosing [10]. Buccal mucoadhesive drug delivery has attained considerable interest in delivering local as well as systemic drug release [11,12] via the localization of the dosage form to the buccal cavity for drug absorption [11,13]. Moreover, localized intra-pocket, retentive, biodegradable, prolonged release buccal mucoadhesive tablets can provide an improved therapeutic efficacy of doxycycline at the site of action while evading off target side effects [10].…”

“…As a result, the absorption and subsequent bioavailability of drugs are improved, leading to minimizing dosage intervals, which is correlated with a better patient compliance [11,15,16]. The loading of MET in orally sustained-release matrix tablets using a continuous melt granulation technique was achieved, ensuring biocompatibility and hemocompatibility [15][16][17].…”